FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3109581377> ?p ?o ?g. }

• W3109581377 endingPage "119" @default.
• W3109581377 startingPage "107" @default.
• W3109581377 abstract "Intravenous iron preparations rapidly correct iron deficiency anemia, with the notable drug class effect of rare, yet potentially life-threatening, administration-related hypersensitivity or anaphylactic reactions. The objective of this comparative study was to assess adverse events associated with four intravenous iron preparations and estimated medical costs, in the US Food and Drug Administration Adverse Event Reporting System (FAERS) database.Cases of hypersensitivity reactions and anaphylaxis/anaphylactic shock associated with iron dextran, iron sucrose, ferumoxytol, and ferric carboxymaltose, spontaneously reported to FAERS (1 January, 2014 to 31 December, 2019), were extracted. The reporting odds ratio lower bound 90% confidence interval (ROR05) > 1 and cases ≥ 5 defined a likely signal for a drug-adverse event association. Adverse event-associated medical costs were estimated using Agency for Healthcare Research and Quality/Healthcare Cost and Utilization Project 2016 data.For hypersensitivity reactions, ferumoxytol and iron dextran had the highest ROR05 values (5.00 and 4.35, respectively) and greatest proportions of associated deaths (7.1% and 5.3%), followed by iron sucrose (ROR05 3.94, deaths 2.4%), and ferric carboxymaltose (ROR05 3.03, deaths 0.2%). For anaphylaxis/anaphylactic shock, ROR05 for cases/deaths were: 39.32/13.4%, ferumoxytol; 37.80/4.5%, iron dextran; 17.60/4.7%, iron sucrose; and 8.77/no deaths, ferric carboxymaltose. Downstream medical costs per adverse event were highest with iron dextran (US$8615) and ferumoxytol (US$8164), followed by iron sucrose (US$4212), and ferric carboxymaltose (US$1832).Reporting rates of hypersensitivity and anaphylaxis with intravenous iron preparations were highest with ferumoxytol and lowest with ferric carboxymaltose in the US FAERS database. Adverse event-related medical costs were highest for iron dextran and ferumoxytol, and lowest for ferric carboxymaltose." @default.
• W3109581377 created "2020-12-07" @default.
• W3109581377 creator A5019868946 @default.
• W3109581377 creator A5024989397 @default.
• W3109581377 creator A5030485203 @default.
• W3109581377 creator A5042218990 @default.
• W3109581377 date "2020-11-25" @default.
• W3109581377 modified "2023-10-11" @default.
• W3109581377 title "Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting System" @default.
• W3109581377 cites W12814060 @default.
• W3109581377 cites W1533705035 @default.
• W3109581377 cites W1965505455 @default.
• W3109581377 cites W2007852467 @default.
• W3109581377 cites W2011415496 @default.
• W3109581377 cites W2035675177 @default.
• W3109581377 cites W2046551865 @default.
• W3109581377 cites W2052727969 @default.
• W3109581377 cites W2064716383 @default.
• W3109581377 cites W2074289946 @default.
• W3109581377 cites W2107516065 @default.
• W3109581377 cites W2118110095 @default.
• W3109581377 cites W2123020477 @default.
• W3109581377 cites W2130938704 @default.
• W3109581377 cites W2145850670 @default.
• W3109581377 cites W2158299492 @default.
• W3109581377 cites W2179358297 @default.
• W3109581377 cites W2216184821 @default.
• W3109581377 cites W2279116486 @default.
• W3109581377 cites W2295940487 @default.
• W3109581377 cites W2408641126 @default.
• W3109581377 cites W2582245763 @default.
• W3109581377 cites W2608364534 @default.
• W3109581377 cites W2611374739 @default.
• W3109581377 cites W2772585576 @default.
• W3109581377 cites W2794162729 @default.
• W3109581377 cites W2802147706 @default.
• W3109581377 cites W2905281157 @default.
• W3109581377 cites W2930013907 @default.
• W3109581377 cites W2977896622 @default.
• W3109581377 cites W2991569063 @default.
• W3109581377 cites W3007610090 @default.
• W3109581377 cites W3010888559 @default.
• W3109581377 cites W3142740423 @default.
• W3109581377 cites W3147067210 @default.
• W3109581377 doi "https://doi.org/10.1007/s40264-020-01022-2" @default.
• W3109581377 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7813702" @default.
• W3109581377 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33237523" @default.
• W3109581377 hasPublicationYear "2020" @default.
• W3109581377 type Work @default.
• W3109581377 sameAs 3109581377 @default.
• W3109581377 citedByCount "14" @default.
• W3109581377 countsByYear W31095813772020 @default.
• W3109581377 countsByYear W31095813772021 @default.
• W3109581377 countsByYear W31095813772022 @default.
• W3109581377 countsByYear W31095813772023 @default.
• W3109581377 crossrefType "journal-article" @default.
• W3109581377 hasAuthorship W3109581377A5019868946 @default.
• W3109581377 hasAuthorship W3109581377A5024989397 @default.
• W3109581377 hasAuthorship W3109581377A5030485203 @default.
• W3109581377 hasAuthorship W3109581377A5042218990 @default.
• W3109581377 hasBestOaLocation W31095813771 @default.
• W3109581377 hasConcept C126322002 @default.
• W3109581377 hasConcept C126838900 @default.
• W3109581377 hasConcept C143409427 @default.
• W3109581377 hasConcept C197934379 @default.
• W3109581377 hasConcept C203014093 @default.
• W3109581377 hasConcept C207480886 @default.
• W3109581377 hasConcept C2775933838 @default.
• W3109581377 hasConcept C2776732101 @default.
• W3109581377 hasConcept C2776974161 @default.
• W3109581377 hasConcept C2777105317 @default.
• W3109581377 hasConcept C2777417653 @default.
• W3109581377 hasConcept C2778248108 @default.
• W3109581377 hasConcept C2909801847 @default.
• W3109581377 hasConcept C3020614022 @default.
• W3109581377 hasConcept C71924100 @default.
• W3109581377 hasConceptScore W3109581377C126322002 @default.
• W3109581377 hasConceptScore W3109581377C126838900 @default.
• W3109581377 hasConceptScore W3109581377C143409427 @default.
• W3109581377 hasConceptScore W3109581377C197934379 @default.
• W3109581377 hasConceptScore W3109581377C203014093 @default.
• W3109581377 hasConceptScore W3109581377C207480886 @default.
• W3109581377 hasConceptScore W3109581377C2775933838 @default.
• W3109581377 hasConceptScore W3109581377C2776732101 @default.
• W3109581377 hasConceptScore W3109581377C2776974161 @default.
• W3109581377 hasConceptScore W3109581377C2777105317 @default.
• W3109581377 hasConceptScore W3109581377C2777417653 @default.
• W3109581377 hasConceptScore W3109581377C2778248108 @default.
• W3109581377 hasConceptScore W3109581377C2909801847 @default.
• W3109581377 hasConceptScore W3109581377C3020614022 @default.
• W3109581377 hasConceptScore W3109581377C71924100 @default.
• W3109581377 hasFunder F4320333966 @default.
• W3109581377 hasIssue "1" @default.
• W3109581377 hasLocation W31095813771 @default.
• W3109581377 hasLocation W31095813772 @default.
• W3109581377 hasLocation W31095813773 @default.
• W3109581377 hasOpenAccess W3109581377 @default.
• W3109581377 hasPrimaryLocation W31095813771 @default.

• next